- Home
- UHT vs ALLO Comparison
UHT vs ALLO Comparison
Compare UHT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UHT | ALLO |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.5M | 483.7M |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | UHT | ALLO |
|---|---|---|
| Price | $38.14 | $1.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 148.5K | ★ 5.6M |
| Earning Date | 10-26-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.86% | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $99,190,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.23 | $255.46 |
| P/E Ratio | $48.34 | ★ N/A |
| Revenue Growth | ★ 0.18 | N/A |
| 52 Week Low | $35.69 | $1.04 |
| 52 Week High | $46.30 | $4.46 |
Technical Indicators
Market Signals| Indicator | UHT | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 26.53 |
| Support Level | $37.96 | N/A |
| Resistance Level | $42.74 | $2.22 |
| Average True Range (ATR) | 0.96 | 0.07 |
| MACD | 0.21 | -0.01 |
| Stochastic Oscillator | 70.86 | 18.82 |
Price Performance
Historical ComparisonAbout UHT Universal Health Realty Income Trust
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).